Paliperidone
Schizoaffective Disorder
Luye Pharma Group Ltd.Small moleculePhase 4 / ApprovedDormant
BBB
78/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 76/ 100
- Competitive Position
- 81/ 100
Competitive context
30 Active assets in the Schizoaffective Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Olanzapine The Royal Ottawa Mental Health Centre | Phase 4 | BBB |
Dexmedetomidine BioXcel Therapeutics Inc | Phase 4 | BBB |
Lurasidone University of Texas Southwestern Medical Center | Phase 4 | BBB |
Raloxifene Iris Sommer | Phase 4 | BBB |
QUETIAPINE Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Paliperidone is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →